A Nature Immunology study describes how an immature T-cell population contributes to persistent, trigger-independent type 2 inflammation in the lungs. Researchers report that progenitor T cells do more than serve as a developmental waystation, actively shaping chronic inflammation after the original stimulus fades. The finding reframes chronic type 2 disease biology by identifying a cellular source capable of maintaining inflammatory programs over time. For drug developers, the work supports therapeutic strategies that target upstream lineage decisions or progenitor persistence rather than only mature effector pathways. The study arrives as type 2 indications—such as asthma and other allergic airway disorders—continue to seek durable disease control beyond initial symptom suppression.